Logo

BeiGene's Brukinsa (zanubrutinib) Receives the US FDA's Accelerated Approval for the Treatment of R/R Marginal Zone Lymphoma

Share this

BeiGene's Brukinsa (zanubrutinib) Receives the US FDA's Accelerated Approval for the Treatment of R/R Marginal Zone Lymphoma

Shots:

  • The approval is based on 2 trials i.e.- P-II MAGNOLIA & P-I/II BGB-3111-AU-003 trial evaluate Brukinsa (160mg- bid or 320 mg- qd) in 66 & 20 patients with R/R MZL who received at least 1 anti-CD20-based regimen
  • Both trial demonstrated ORR (56% & 80%)- CR rate (20% & 20%) based on assessment using CT scan- m-DoR (not yet reached) @median follow-up (8.3 & 31.4mos.)- 85% & 72% of responders still in remission @12mos. Based on assessment prioritizing PET-CT scan- ORR (67%)- CR rate (26%) in MAGNOLIA trial
  • The therapy marks 3rd FDA approval in the US & is currently being evaluated in multiple studies globally as a monothx. or in combination with other therapies for multiple B cell malignancies

  | Ref: Businesswire | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions